

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended): A Neisserial bleb preparation derived from an lgtB⁻ neisserial strain ~~with an L2 LOS immunotype or a neisserial strain with an L3 LOS immunotype and wherein the strain is lgtB⁻; or a Neisserial bleb preparation comprising a combination of blebs derived from a neisserial strain with an L2 LOS immunotype and a neisserial strain with an L3 LOS immunotype, optionally wherein each strain is lgtB⁻.~~
2. (Currently amended): The Neisserial bleb preparation of claim 1, comprising a ~~neisserial strain selected from the group of a meningococcal strain and a strain of serogroup B.~~
3. (Currently amended): The Neisserial bleb preparation of claim 1, wherein the neisserial strain(s) cannot synthesize capsular polysaccharide.
4. (Currently amended): The Neisserial bleb preparation of claim 3, wherein ~~the neisserial strain(s) have at least one of the following capsular polysaccharide gene[[s]] of the neisserial strain is downregulated in expression, or deleted compared to the native strain(s) from which the neisserial strain is they are derived, wherein the at least one downregulated capsular polysaccharide gene is selected from the group of: ctrA, ctrB, ctrC, ctrD, synA, synB, synC, and siaD~~saiD; and ~~wherein L2 and L3 blebs are both present, and optionally the strains from which they are derived preferably have the same capsular polysaccharide gene downregulated in expression in each strain.~~
5. (Currently amended): The Neisserial bleb preparation of claim 1, wherein ~~the neisserial strain(s) have either or both of the following at least one lipid A gene[[s]] of the neisserial strain are downregulated in expression, or deleted, compared to the native strain(s) from which the neisserial strain is they are derived, wherein the lipid A gene is selected from either or both of msbB and htrB; msbB or htrB; and wherein L2 and L3 blebs are both~~

~~present; and optionally the strains from which they are derived have the same lipid A gene(s) downregulated in expression in each strain.~~

6. (Currently amended): The Neisserial bleb preparation of claim 1, wherein ~~the neisserial strain(s) have 1~~ one or more of the following outer membrane protein genes of the neisserial strain are downregulated in expression ~~or deleted~~, compared to the native strain(s) from which the neisserial strain is ~~they are derived~~, wherein the one or more downregulated outer membrane protein genes are selected from the group of: porA, porB, opA, opC, pilC or frpB; and ~~wherein where L2 and L3 blebs are both present, and optionally the strains from which they are derived preferably have the same outer membrane protein gene(s) downregulated in expression in each strain.~~

7. (Currently amended): The Neisserial bleb preparation of claim 6, wherein the neisserial strain(s) ~~have any of the following~~ has a combination[[s]] of outer membrane protein genes downregulated in expression, wherein the combination of downregulated outer membrane protein genes is selected from the group of ~~or deleted~~, compared to the native strain(s) ~~from which they are derived~~: PorA and OpA, PorA and OpC, OpA and OpC, PorA and OpA and OpC, PorA and FrpB, OpC and FrpB, OpA and FrpB, PorA and OpA and OpC and FrpB.

8. (Currently amended): The Neisserial bleb preparation of claim 1, wherein ~~the neisserial strain(s) have 1~~ one or more of the following outer membrane protein antigens in the neisserial strain is upregulated in expression as compared to the strain from which the neisserial strain is derived, wherein the one or more upregulated outer membrane protein antigens are selected from the group of: NspA, TbpA low, TbpA high, Hsf, Hap, OMP85, PilQ, NadA, LbpA, MltA; and ~~wherein where L2 and L3 blebs are both present, and optionally the strains from which they are derived have one or more different outer membrane protein antigens upregulated in expression in each strain.~~

9. - 13. (Cancelled):

14. (Currently amended): The Neisserial bleb preparation of claim 1 or the LOS preparation of claim [[12]]1, wherein the LOS contained therein is conjugated to a source of T-helper epitopes.

15. (Currently amended): The Neisserial bleb preparation of claim 14, wherein the LOS is conjugated to the source of T-helper epitopes by obtained through a process of intra-bleb cross-linking.

16. (Currently amended): An immunogenic composition ~~or vaccine~~ comprising the Neisserial bleb preparation ~~or the LOS preparation~~ of claim 1, and a pharmaceutically acceptable excipient.

17. (Currently amended): The immunogenic composition ~~vaccine~~ of claim 16, comprising an adjuvant, ~~preferably aluminium hydroxide, or 3D-MPL and aluminium phosphate.~~

18. (Currently amended): The immunogenic composition ~~vaccine~~ of claim 16, further comprising one or more conjugated capsular polysaccharides or oligosaccharides derived from a bacterium ~~the strains~~ selected from the group of: meningococcus serogroup A, meningococcus serogroup C, meningococcus serogroup W-135, meningococcus serogroup Y, and *H. influenzae* type b.

19. (Withdrawn-currently amended): A process of manufacturing the immunogenic composition ~~Neisserial bleb preparation vaccine~~ of claim 16, comprising the steps of:
_____ culturing a lgtB⁻ Neisserial strain with an L3 LOS immunotype ~~the Neisserial strain(s) of claim 11;~~
_____ isolating blebs therefrom; ~~optionally combining L2 and L3 blebs;~~ and
_____ formulating the blebs with a pharmaceutically acceptable excipient.

20. (Withdrawn-currently amended): The process of claim 19, comprising isolating the blebs wherein the isolation step is carried out by extracting with 0.1%, about 0-0.5%, about 0.02-0.4, about 0.04-0.3, about 0.06-0.2, or about 0.08-0.15% deoxycholate.

21. - 52. (Cancelled):

53. (Previously presented): The Neisserial bleb preparation of claim 14 wherein the source of T-helper epitopes comprises a protein or outer membrane protein.

54. - 55. (Cancelled)

56. (New) The Neisserial bleb preparation of claim 1, further comprising a Neisserial bleb preparation derived from an lgtB⁻ neisserial strain with an L2 LOS immunotype.

57. (New) The Neisserial bleb preparation of claim 56, wherein the strains from which the L2 and L3 LOS are derived each have at least one capsular polysaccharide gene downregulated in expression, wherein the at least one downregulated capsular polysaccharide gene is selected from the group of: ctrA, ctrB, ctrC, ctrD, synA, synB, synC, and siaD.

58. (New) The Neisserial bleb preparation of claim 57, wherein both strains have the same capsular polysaccharide gene downregulated in expression.